<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168568</url>
  </required_header>
  <id_info>
    <org_study_id>VASCEND</org_study_id>
    <nct_id>NCT03168568</nct_id>
  </id_info>
  <brief_title>Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction</brief_title>
  <acronym>VASCEND</acronym>
  <official_title>Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction: A Double-blind Randomized Controlled Phase IV Trial (VASCEND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate whether valsartan/sacubitril leads to a superior&#xD;
      improvement in endothelial function and endocrine status compared to valsartan alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Valsartan/sacubitril (Entresto®; LCZ696) is a first-in-class angiotensin receptor neprilysin&#xD;
      inhibitor (ARNI) that has recently been approved for the treatment of chronic heart failure&#xD;
      with reduced ejection fraction (HFrEF). The drug consists of a 1:1 complex of the angiotensin&#xD;
      receptor blocker (ARB) valsartan and the neprilysin inhibitor sacubitril. In a recent&#xD;
      randomized controlled trial in patients with heart failure and reduced ejection fraction&#xD;
      (PARADIGM-HF), valsartan/sacubitril significantly reduced all-cause and cardiovascular&#xD;
      mortality as well as hospitalizations for heart failure compared to enalapril. The precise&#xD;
      reason why combined angiotensin receptor and neprilysin blockade is superior to ACE blockade&#xD;
      is still unclear and knowledge of the mechanisms involved would provide further insight which&#xD;
      patients with symptomatic heart failure will particularly benefit from valsartan/sacubitril.&#xD;
      On the one hand, many of the peptides affected by neprilysin blockade act on vascular&#xD;
      endothelial cells. On the other, neprilysin inhibition may induce significant endocrine&#xD;
      changes with a shift to more favorable hormonal profile in HFrEF patients. Detailed studies&#xD;
      on the vascular and endocrine effects of valsartan/sacubitril in humans are lacking so far.&#xD;
      The investigators hypothesize that valsartan/sacubitril results in an incremental improvement&#xD;
      of endothelial dysfunction and endocrine imbalance over valsartan in patients with heart&#xD;
      failure with reduced ejection fraction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Actual">September 5, 2020</completion_date>
  <primary_completion_date type="Actual">September 5, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in flow-mediated vasodilatation (FMD)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Difference in flow-mediated vasodilatation (FMD, percent dilatation of brachial artery after blood pressure cuff occlusion) between the valsartan/sacubitril and valsartan group as assessed at the final study visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in flicker-induced vasodilatation of retinal arterioles and venules</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Valsartan/Sacubitril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan-Sacubitril 50mg/100mg twice daily, titrated to 200mg twice daily p.o. Duration of product administration: 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan 40mg/80mg twice daily, titrated to 160mg twice daily p.o Duration of product administration: 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan/Sacubitril or placebo</intervention_name>
    <description>tablet (double dummy)</description>
    <arm_group_label>Valsartan/Sacubitril</arm_group_label>
    <other_name>Entresto®; LCZ696</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan or placebo</intervention_name>
    <description>tablet (double dummy)</description>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Diovan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥ 18 years of age, male or female, with a diagnosis of symptomatic heart&#xD;
             failure (NYHA class II-IV) per ESC heart failure guidelines&#xD;
&#xD;
          2. LVEF ≤ 40%&#xD;
&#xD;
          3. Established guideline-recommended therapy with an ACEI, ARB and a beta-blocker, as&#xD;
             clinically indicated and tolerated, at stable doses for at least 3 weeks prior to&#xD;
             inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity or allergy to any of the study drugs&#xD;
&#xD;
          2. History of angioedema.&#xD;
&#xD;
          3. Sitting systolic blood pressure &lt;90 mmHg at Visit 1 (screening) or Visit 2&#xD;
             (randomization)&#xD;
&#xD;
          4. Current acute decompensated HF (exacerbation of chronic HF manifested by signs and&#xD;
             symptoms that may require intravenous therapy).&#xD;
&#xD;
          5. Estimated GFR &lt; 20 mL/min/1.73m2&#xD;
&#xD;
          6. Serum potassium &gt; 5.5 mmol/L at Visit 1 (screening) or Visit 2 (randomization).&#xD;
&#xD;
          7. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other&#xD;
             major CV surgery, percutaneous coronary intervention (PCI) or carotid angioplasty&#xD;
             within the 3 months prior to Visit 1.&#xD;
&#xD;
          8. Coronary or carotid artery disease likely to require surgical or percutaneous&#xD;
             intervention within the 3 months after Visit 1.&#xD;
&#xD;
          9. Implantation of a cardiac resynchronization therapy device (CRTD) within 2 months&#xD;
             prior Visit 1 or intent to implant a CRTD within next 3 months.&#xD;
&#xD;
         10. History of heart transplant, on a transplant list or with ventricular assistance&#xD;
             device (VAD).&#xD;
&#xD;
         11. Presence of significant endocrine diseases.&#xD;
&#xD;
         12. Presence of active acute infectious diseases.&#xD;
&#xD;
         13. Known narrow-angle glaucoma&#xD;
&#xD;
         14. Known epilepsy&#xD;
&#xD;
         15. Cimino-shunt operation on both arms&#xD;
&#xD;
         16. Pregnancy, intention thereof during study; lack of sufficient contraception;&#xD;
             breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Heart Center Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

